Compare Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily 20 Year Treasury Bull 3X Shares vs Viatris Inc — how do they compare? Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.78, while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and Viatris Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| TMF | VTRS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $44.14 | $17.86 |
52-Week Low | $30.59 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $30.76, up 0.38% today, but technical indicators are predominantly bearish with moving averages signaling sell. Key financial ratios like P/E and P/S are unavailable, and the fund's leveraged structure amplifies volatility. Recent news highlights significant long-term losses, with a $10,000 investment five years ago now worth about $1,527, underscoring the risks of daily rebalancing.
The outlook for TMF is highly speculative, offering potential gains if long-term Treasury yields decline, but it carries extreme risk due to leverage decay and interest rate sensitivity. Investors should avoid long-term holdings, as the fund is suited only for short-term traders who can manage amplified losses. Macroeconomic shifts in bond markets remain the primary driver of performance.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
